

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) (RAC1)	<i>In vitro</i> , zebrafish and mouse studies suggest dehydro- $\alpha$ -lapachone and its analogs could help treat cancer. <i>In vitro</i> screening and testing in human cell lines and zebrafish identified a dehydro- $\alpha$ -lapachone as an inhibitor of RAC1 activity that decreased endothelial cellular adhesion. In two mouse models of mammary cancer, the compound lowered tumor growth and tumor vasculature density compared with vehicle. Next steps could include synthesizing and testing dehydro- $\alpha$ -lapachone analogs in animal models of cancer.	Patented by Massachusetts General Hospital; available for licensing	Garkavtsev, I. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online June 27, 2011; doi:10.1073/pnas.1104225108 <b>Contact:</b> Igor Garkavtsev, Massachusetts General Hospital and Harvard Medical School, Cambridge, Mass. e-mail: <a href="mailto:igorg@steele.mgh.harvard.edu">igorg@steele.mgh.harvard.edu</a>
<p><i>SciBX</i> 4(27); doi:10.1038/scibx.2011.764 Published online July 14, 2011</p>				